## MTD: Mettler-Toledo International, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.7% below STRENGTH zone (4.0-10.0%); PEG 3.64 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1305.85)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Mettler-Toledo International Stock Slides 8.3% With A 8-Day Losing Spree**
- Source: Trefis | 20251209T080829 | Neutral | Relevance: 99%
- Mettler-Toledo International stock has seen an 8.3% decline, marking an eight-day losing streak. The article provides this key financial information regarding the company's recent stock performance.

**2. Goldman Sachs Initiates Coverage on Mettler-Toledo (MTD) with Ne**
- Source: GuruFocus | 20251209T140824 | Somewhat-Bullish | Relevance: 98%
-  Goldman Sachs has initiated coverage on Mettler-Toledo International Inc. (MTD) with a 'Neutral' rating and a price target of $1,475.00 USD. This report highlights recent analyst activities and forecasts for MTD, noting an average target price of $1,490.41 from 13 analysts, suggesting an upside of 7.89% from its current price. Mettler-Toledo specializes in weighing and precision instruments for life sciences, industrial, and food retail sectors.

**3. Mettler-Toledo International, Inc. (NYSE:MTD) Given Average Recommendation of "Hold" by Brokerages**
- Source: MarketBeat | 20251206T200857 | Neutral | Relevance: 98%
- Mettler-Toledo International, Inc. (NYSE:MTD) has received an average "Hold" rating from thirteen brokerages, with an average twelve-month target price of $1,419.55. Despite some analysts raising price targets to "buy" or "overweight," the consensus remains "Hold." The company recently surpassed Q3 earnings estimates with EPS of $11.15 and revenue of $1.03 billion, and provided positive Q4 and FY2025 EPS guidance, yet insider sales of approximately 19,565 shares totaling $28.7 million have occurred over the last three months.

**4. Marshall Wace LLP Reduces Holdings in Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251206T115110 | Neutral | Relevance: 98%
-  Marshall Wace LLP decreased its stake in Mettler-Toledo International, Inc. by 36.9% in Q2, now owning 59,820 shares worth $70.27 million. Other institutional investors have also adjusted their positions in the medical instruments supplier. Insiders Gerry Keller and Elisha W. Finney sold shares recently, reducing their holdings.

**5. Mirabella Financial Services LLP Sells 2,314 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251206T115410 | Neutral | Relevance: 98%
-  Mirabella Financial Services LLP significantly reduced its stake in Mettler-Toledo International, Inc. (NYSE:MTD) by selling 2,314 shares, lowering its position by 74.8% in the second quarter. Following the sale, the firm now holds 779 shares valued at $919,000. Other institutional investors have also adjusted their holdings in the medical instruments supplier, which recently reported strong quarterly earnings and has an average analyst rating of "Hold."

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $1550 | $0 | 0% |
| 2025-11-10 | Citigroup | $1700 | $1600 | +6% |
| 2025-11-10 | Barclays | $1600 | $1350 | +19% |
| 2025-11-10 | Wells Fargo | $1400 | $1200 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |
| 2025-11-10 | Citigroup | main | Buy |
| 2025-11-10 | Barclays | main | Overweight |
| 2025-11-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($1.28M) |
| Sells | 6 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+1.4%)
- Blackrock Inc.: 9.2% (-3.1%)
- State Street Corpora: 4.7% (-0.5%)
- Capital Internationa: 4.2% (+1.2%)
- Bank Of New York Mel: 4.0% (-9.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.5% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.6x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.64 signals overvaluation risk, limited margin of safety. Forward P/E 30.2x stretched relative to 8% growth. Quality metrics strong (ROE 30%, ROA 20%, margin 21%). Analyst sentiment positive (4 raises, avg +13%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $28.5B |
| Beta | 1.40 |
| 52W Range | $946.69 - $1525.17 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.64 |
| Forward P/E | 30.2 |
| Current P/E | 32.7 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.1% to -5.7% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.7pp (needs >4.0% for momentum thesis). AM_20 at -3.7% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-10.18), momentum weakening. RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.66% (CS: 10) | Weak |
| RSI_14 | 41.1 | Neutral |
| MACD Histogram | -10.18 | Bearish |
| vs SMA20 | 0.963x | Below |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1381.37
- **Stop Loss:** $1305.85 (5.5% risk)
- **Target:** $1456.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 6
- **Position Value:** $8,288.22
- **Portfolio %:** 8.29%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-05 (Est: $12.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $10.66 | $11.15 | +4.6% |
| 2025Q2 | $9.60 | $10.09 | +5.1% |
| 2025Q1 | $7.88 | $8.19 | +3.9% |
| 2024Q4 | $11.72 | $12.41 | +5.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*